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Recent ﬁndings have suggested that the mucosal barrier is a
primary focus of disease activity in celiac disease. Alongside
the well-established remodeling of the small intestinal
architecture, focal epithelial barrier defects occur with
increased apoptosis and an altered tight junction–mediated
permeability. Barrier-forming claudins are down-regulated
while the channel-forming claudins are up-regulated, both
causing a loss of ions and water to the gut lumen. An inti-
mately regulated transcellular passage of gliadin peptides is
needed for celiac disease development. As a central orga-
nizer of proteins related to barrier function, the role of
epithelial polarity regulators is discussed.
In celiac disease (CD) a T-cell–mediated response to
gluten is mounted in genetically predisposed individuals,
resulting in a malabsorptive enteropathy histologically
highlighted by villous atrophy and crypt hyperplasia.
Recent data point to the epithelial layer as an under-
rated hot spot in celiac pathophysiology to date. This
overview summarizes current functional and genetic
evidence on the role of the epithelial barrier in CD,
consisting of the cell membranes and the apical junc-
tional complex comprising sealing as well as ion and
water channel-forming tight junction proteins and the
adherens junction. Moreover, the underlying mecha-
nisms are discussed, including apoptosis of intestinal
epithelial cells, biology of intestinal stem cells, alter-
ations in the apical junctional complex, transcytotic
uptake of gluten peptides, and possible implications of a
defective epithelial polarity. Current research is directed
toward new treatment options for CD that are alterna-
tives or complementary therapeutics to a gluten-free
diet. Thus, strategies to target an altered epithelial
barrier therapeutically also are discussed. (Cell Mol
Gastroenterol Hepatol 2017;3:150–162; http://dx.doi.org/
10.1016/j.jcmgh.2016.12.006)
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y deﬁnition, celiac disease (CD) is an immune-
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http://dx.doi.org/10.1016/j.jcmgh.2016.12.006Bmediated small intestinal disorder with a strong
genetic component. In genetically predisposed individuals it
is triggered by the ingestion of gluten-containing food. It isassumed that gluten is responsible for CD induction
together with one or more other, nondietary factors that
have not been identiﬁed yet. Gluten is a mixture of proteins
found in grains such as wheat, barley, and rye, and includes
peptide sequences that have the potential to elicit a small
intestinal HLA-DQ2– or HLA-DQ8–restricted T-cell response.
The only accepted treatment of CD is the adherence to a
strict gluten-free diet (GFD). Diagnosis is established on the
basis of the following: (1) a positive transglutaminase-IgA
serology; (2) a duodenal histology showing villous atro-
phy, crypt hyperplasia, and intraepithelial lymphocytosis;
and (3) by documenting a clinical improvement after
introduction of a GFD.1,2
As documented by large epidemiologic studies in
Europe, North America, and India, the burden associated
with CD on the society is signiﬁcant because it affects
approximately 1% of the population and is associated with
signiﬁcant morbidity secondary to malabsorption and a
moderately increased risk of developing malignancy.3–6
This review focuses on what is known in CD patho-
physiology with respect to the intestinal barrier. Barrier
function has been shown to be altered in CD for many
years already.7–9 However, it has been a matter of debate
regarding its signiﬁcance ever since (ie, whether barrier
function contributes to the development of CD or if it is
merely a phenomenon secondary to the CD immune
response). Thus, this article summarizes the factors that
contribute to barrier function in CD, discusses its
presumed functional outcome, and refers to current and
future treatment strategies that can be deduced from these
insights. In this review we refer to a hierarchy of compo-
nents of the intestinal barrier. The mucosal barrier relates
to the barrier the mucosa imposes as a whole (ie, including
structures such as lamina propria cells). In contrast, the
epithelial layer or epithelial barrier relates solely to the
single layer of intestinal epithelial cells. The term barrier
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the tight junction) imposes on the mucosal immune
system.Figure 1. Binding of a gliadin epitope to the HLA complex.
Gliadin fragments are deamidated by tissue transglutaminase
(ie, a glutamine is transformed to a glutamate), thereby add-
ing an additional negative charge to the epitope (blue circle).
This facilitates binding to the DQ2 groove of the major
histocompatibility complex molecule. Here, binding of the
glia-a1 fragment to HLA-DQ2 is exempliﬁed. However, this
principle holds true for various oligopeptide sequences
within a-, g-, and u-gliadin sequences, and also for binding
to HLA-DQ8. Amino acids are shown in the 1-letter code with
Q, glutamine and E, glutamate. The recognition motif of
tissue transglutaminase within the unprocessed gliadin
peptide (Q-X-P) is denoted in red letters. APC, antigen-
presenting cell, P1.P9, binding positions within the DQ2
complex.Genetics
The risk of ﬁrst-degree relatives being affected by CD was
shown to be 7.5% in a recently published meta-analysis.10
Having at least 2 ﬁrst-degree relatives with CD in the family
increases CD risk to 17%.11 Importantly, monozygotic twins
show a concordance as high as 75% for CD development,
which is considerably higher than respective ﬁgures in other
autoimmune diseases such as multiple sclerosis, Crohn’s
disease, or type I diabetes mellitus.12 Forty percent of the
genetic risk is conferred by genes encoding for the HLA class
II molecules HLA-DQ2 (DQ2.5-DQA1*0501-DQB1*0201 or
DQ2.2-DQA1*0201-DQB1*0202) and HLA-DQ8 (DQA1*
0301-DQB1*0302).13–15 The remaining 60% are encoded by
non-HLA genes, each of which is estimated to contribute only
a small effect.16
Making use of single-nucleotide polymorphisms (SNPs)
as markers of association, genome-wide association studies
(GWAS) were performed to identify further genes respon-
sible for CD. The ﬁrst GWAS included 778 CD patients and
1422 controls and analyzed 310,605 SNPs, thereby identi-
fying a locus on chromosome 4 harboring the interleukin
(IL)2 and IL21 genes.17 Further GWAS followed with
increasing resolution secondary to recruitment of several
thousand celiac patients and higher resolving chips that
included more than 0.5 million SNPs. These recent chips
focused on distinct regions of the genome, thereby uncov-
ering a total of 39 loci that contained 115 genes.18,19
Several conclusions can be drawn from these GWAS. First,
most of the genes identiﬁed are implicated in the control of
the adaptive immune response, including genes for T-cell
activation as well as cytotoxicity, IL21 production, IgA
response, and B cells. Second, the function of a considerable
number of genes identiﬁed in the screen is to date
unknown and will be the subject of future research as
exempliﬁed by recent work from Kumar et al.20 The
investigators applied a co-expression algorithm and thereby
identiﬁed 4 CD-associated genes with as-yet unknown
function, which now are predicted to be involved in intes-
tinal barrier function, especially in the actin-cytoskeleton
rearrangement and cell–cell adhesion pathways. In this
regard, an insight published more than 20 years ago should
be recalled, namely that healthy ﬁrst-degree siblings of CD
patients also show a signiﬁcantly altered barrier function.7
Albeit methodologically different, both studies came to the
conclusion that mechanisms determining the intestinal
barrier function in CD contribute to disease development
rather than being secondary to it. Third, approximately
50% of the associated SNPs affect the expression of nearby
genes (ie, expression quantitative traits loci), which implies
that deregulated gene expression plays a signiﬁcant role in
CD pathogenesis. Fourth, there is a major overlap of genes
involved in CD pathogenesis with genes involved in the
development of other autoimmune pathologies including
type I diabetes mellitus, rheumatoid arthritis, Crohn’sdisease, and ulcerative colitis.21,22 This certainly reﬂects
clinical experience because a high percentage of CD patients
suffer from one or more additional autoimmune diseases.
Main Trigger of Celiac Disease: Gluten
Glutens are storage proteins occurring in grains of
wheat, barley, rye, and archaic wheats. Although the alcohol-
insoluble fraction is referred to as glutenins and is respon-
sible for the baking properties of the respective dough
secondary to its gluing and dispersing characteristics, the
gliadins are alcohol-soluble and carry most of gluten’s well-
described antigenic properties. Wheat grains express a-, g-,
and u-gliadins, as well as low- and high-molecular-weight
glutenins. The proportion of glutamine and proline is
remarkably high (30% and 15% of all amino acids,
respectively), which leads to modiﬁcation by tissue trans-
glutaminase and then contributes to establishing strong
interactions of gluten epitopes with the major histocom-
patibility complex II complex (Figure 1), and results in
resistance to degradation by gastrointestinal endopepti-
dases, thus facilitating the advent of large immunogenic
gluten fragments at the epithelial barrier.
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Both the genetic susceptibility and the presence of
dietary gluten are essential factors for CD to develop.
However, these 2 factors alone are not sufﬁcient. Consistent
with this notion, a signiﬁcant number of CD patients are not
diagnosed before age 40.23 It has not yet been uncovered
why these patients who are genetically prone to develop CD
since their ﬁrst day of life and who are consuming gluten
since their ﬁrst year of life do not develop overt disease
much earlier.
In this regard, another poorly understood phenomenon
related to CD etiology, known as the Swedish epidemic, is
worth mentioning. Starting in the late 1980s, CD incidence
in Sweden was increasing by 3-fold within less than 5 years
and turned back to the initial incidence level in the late
1990s.24 Surveys that monitored habits of the affected in-
dividuals of the epidemic were performed to engage po-
tential causes for this transient shift in CD incidence and
thereby to uncover additional CD etiologic factors.25 Three
major hypotheses were brought forward, as follows: (1) the
protective function of breastfeeding and timing of weaning;
(2) amount of gluten given during the introductory period;
and (3) repeated infectious episodes.
Although the ﬁrst 2 hypotheses were related to the in-
duction of oral tolerance, the third hypothesis was associated
with infection-related alterations of the intestinal barrier. In a
subsequent effort to identify infant feeding strategy as amajor
determining factor in CD development, 2 large prospective
multicenter initiatives (PreventCD and CELIPREV) involving
more than 1700 newborns were initiated and generated
convincing evidence that neither breastfeeding habits nor the
timing or dosing of gluten during the introductory phasewere
relevant for later CD development.26,27 However, a recent
case–control study involving a Swedish CD cohort realized a
gluten dosage effect when they analyzed gluten consumption
in children who were followed up until age 8.28
Remarkably, the remaining assumption that previous
gastrointestinal (GI) infections could trigger CD development
was much older and had its origin in studies by Kagnoff
et al,29 who identiﬁed sequence similarities between peptide
sequences of gluten and adenovirus peptides. They also were
substantiated epidemiologically by several studies including
a recent one on a cohort of more than 70,000 childrenwith an
increased CD risk when experiencingmore than 10 infections
up to the age of 18 months, a study that suggested a role for
rotavirus infection, and a third study that reported an asso-
ciation with Campylobacter and CD in military personal.29–32
However, it still is unclear whether infections push celiac
prevalence secondary to a mechanism resembling molecular
mimicry or by alteration of the intestinal barrier, the latter of
which being favored by recent studies.33–35
Intestinal Epithelial Cells: The
Mainstay of the Intestinal Barrier
The histopathologic hallmark of CD is small intestinal
villous atrophy and crypt hyperplasia. Given the fact that
mucosal architecture is altered severely, epithelial cell
turnover turns into the focus of CD pathobiology. Researchfrom the past decade has identiﬁed the Lgr5-positive crypt
base columnar cells (CBCs) as the intestinal stem cell
generating absorptive as well as secretory enterocytes that
then are pushed upward along the crypt–villous axis,
reaching the villous tip within 5 days where they are
extruded.36 Fueling of this conveyor belt depends not only
on the 15 CBCs situated in each crypt base, but also on direct
contact of the CBCs to the 10 Paneth cells nursing the CBCs
with growth factors of the epidermal growth factor (EGF),
Wnt, and Notch signaling pathway and inhibitors of bone
morphogenetic protein (Bmp) signaling.37,38 In Crohn’s
disease, Paneth cell dysfunction is well established with
autophagy and endoplasmic reticulum stress as 2 pivotal
mechanisms that are altered genetically (Figure 2). In celiac
disease Paneth cell dysfunction also is established, specif-
ically lysozyme was found to be secreted at reduced levels
into the crypt lumen resembling the Crohn’s Paneth cell
defect, where mutated ATG16L1 leads to altered secretory
granule secretion and dysregulated autophagy. However, a
mutation in ATG16L1 is not associated with celiac disease,
leaving the mechanism open for future research.39,40
Another measure of Paneth cell activity, expression of
antimicrobial a-defensins, showed a reduction of a-defensin
expression in complicated CD.41 However, it currently is
unclear whether these alterations are primary defects
associated with a celiac genotype or if they are secondary to
the small intestinal inﬂammation caused by the immune
response of CD. Nevertheless, evidence was brought forward
that growth factor–dependent signaling within the intestinal
stem cell compartment is shifted signiﬁcantly, including the
Wnt- and EGF-dependent b-catenin–transcription factor
signaling and downstream c-myc activation (Figure 2).42–44
Wnt signaling is targeted indirectly by distinct activity
modulation of the histone H3 methyltransferase polycomb
repressive complex-2, which includes the members Sup-
pressor of zeste 12 (SUZ12) and Enhancer of zeste homolog
2 (EZH2), the ﬁrst being down-regulated in celiac disease.45
Concurrent down-regulation of the Bmp receptor ligand
Bmp4 presumably contributes to crypt proliferation because
inhibition of Bmp signaling was shown to be associated with
ectopic crypt formation.43,46 Similarly, c-myc gene expres-
sion and expression of EGF signal transductors were found
increased in celiac disease, which is in accordance with
ﬁndings that conditional gene deletion of c-myc causes loss
of intestinal crypts, and up-regulation of EGF signaling leads
to an ampliﬁcation of the stem cell niche.42,44,47,48 Targeting
the positioning of the zone where intestinal epithelia
convert from crypt enterocytes to villous enterocytes is
another potential mechanism that was discussed in celiac
disease because ephrin-B2 expression was found to be
increased. Interaction of Eph receptors (expressed in the
crypts secondary to local Wnt signaling) and ephrin ligands
(expressed in the transitory zone) contributes to positioning
as a result of cell repulsion secondary to direct cell-to-cell
interaction of these membrane proteins.42,49
In addition to developmental transformations of the
crypt–villous axis, one major focus of CD research has been
the occurrence of focal defects in the epithelial layer within
celiac lesions. Many groups have reported an increased
Figure 2. Crypt–villous axis of the small intestinal mucosa and alterations of the stem cell compartment found in celiac
disease. For detailed explanations refer to the corresponding text. Altered signaling components relevant for celiac disease
are highlighted in red, and those for Crohn’s disease are shown in green. c-myc, Myc proto-oncogen; Mf, macrophage;
SG, secretory granule; BMPR I and II, BMP receptor I and II; EZH22 and SUZ12, polycomb proteins (histone methyl-
transferases); ATG16L1, autophagy-related protein 16-1; TCF1, transcription factor-1; EGFR (erb-b), epidermal growth factor
receptor; PI3K, phosphatidylinositol 3-kinase; b-cat, b-catenin.
March 2017 Epithelial Barrier in Celiac Disease 153number of apoptotic intestinal epithelial cells (IECs) in the
celiac mucosa.50–52 Various steps in the signal transduction
initiating apoptosis are deferred, including the down-
regulation of anti-apoptotic Bcl-2.53 However, a major
switch for celiac apoptosis is caused by IEC secretion of
IL15 inducing up-regulation of FAS ligand in intraepithelial
lymphocytes as well as epithelial FAS.54,55 Second, IL15
cooperatively with an a-gliadin 19mer peptide elicits
expression of major histocompatibility complex class I
chain–related gene-A (MIC-A), a transmembrane protein
that is categorized as an unconventional HLA class I mole-
cule and functions as a stress signal on gastrointestinal
epithelia.56,57 MIC-A–expressing IECs are recognized by
intraepithelial lymphocytes carrying an NKG2D-receptor,
thereby causing IEC cytotoxicity. Another mechanism
contributing to IEC apoptosis that also is independent ofHLA class II restriction is triggered by a decapeptide
sequence within a-gliadin and involves HLA A2–restricted,
CD8þ Fas ligandþ T cells.58
Interestingly, an erroneous sequence of events in auto-
phagy, which is the mechanism by which cells disassemble
dysfunctional cellular components and thus speciﬁcally
affects long-living cells such as, for example, Paneth cells,
was shown to be a key mechanism responsible for epithelial
dysfunction in Crohn’s disease, another autoimmune
inﬂammatory bowel disease affecting the small intestine.
Although the respective defects of the autophagy machinery
identiﬁed in Crohn’s disease were not found to be relevant
for CD pathogenesis,59,60 recent work on CD biopsy
specimens showed 107 of 214 autophagy-related genes
to be expressed differentially, thereby suggesting that
autophagy might in fact play a prominent role in CD.61
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and Their Potential Causes
In the intestine, the epithelial monolayer constitutes a
barrier consisting of the epithelial cell membranes and the
apical junctional complex that deﬁnes the paracellular
barrier. It is localized to the apical half of the lateral
membrane of the IEC and is assembled from the tight
junction (TJ) and the adherens junction (AJ). Although
adherens junctions and desmosomes convey the mechanical
linkage between adjacent cells, most TJ proteins seal the
paracellular cleft against unlimited passage of solutes and
water.62,63 Contrary to that, some TJ proteins form—in
different epithelial tissues—paracellular channels with aFigure 3. Composition of the apical junction and localizati
comprises the TJ and the adherens junction. Main mammalian T
and important AJ proteins are cadherin and nectin. Although
occludin) deﬁne the paracellular barrier or channel function for s
catenin, nectin) provide a mechanical linkage between neighborin
convey barrier function. Virtually all TJ and adherens junction pro
rap1) either interacting as scaffolds with the actin cytoskeleton (g
the apical (red) or basolateral (blue) cell side.preference for cations (claudin-2, claudin-10b, claudin-
15), anions (claudin-10a, claudin-17), and water
(claudin-2).64–67 In various pathologic conditions, the se-
lective paracellular solute transport can be increased as a
result of down-regulation of barrier-forming claudins and/
or up-regulation of channel-forming claudins (Figure 3).68
Evidence for a defective epithelial barrier in CD comes
from experimental approaches that determined ex vivo bar-
rier function of CD mucosae by one-path impedance spec-
troscopy. This method allows for speciﬁc determination of
the epithelial part of the transepithelial electrical resistance
of the small intestinal mucosa.52,69 Interestingly, epithelial
barrier function was found to be reduced signiﬁcantly,
which was reversed partially in the group of GFD-adherenton of polarity complexes in epithelia. The apical junction
J proteins are claudin-1 to claudin-27, occludin, and JAM-A,
the proteins featuring 4 transmembrane domains (claudins,
olute and water diffusion, the single-spanning proteins (JAMs,
g cells. Note that JAMs are considered TJ proteins but do not
teins are linked via intracellular proteins (ZO-1, Par-3, catenin,
rey dots) and/or as polarity complexes with the membranes of
Table 1.Total Transmural Electrical Resistance in Celiac
Disease (Rt, Corresponding to Common Transmural
Electrical Resistance), Consisting of Epithelial (Repi)
and Subepithelial Resistance (Rsub), as Determined
by One-Path Impedance Spectroscopy
Rt, U$cm2 Repi, U$cm2 Rsub, U$cm2 n
Control 59.8 ± 2.3 25.7 ± 1.3 34.2 ± 1.4 15
Active CD 36.6 ± 3.3a 13.3 ± 1.1a 23.4 ± 2.3a 8
Treated CD 52.1 ± 4.3b 21.6 ± 2.8b 30.5 ± 2.7NS 11
NOTE. All data represent means ± SEM. Control and active
CD are data from Schumann et al52 treated CD are original
unpublished data.
NS, not signiﬁcantly different; Repi, epithelial resistance; Rsub,
subeppithelial resistance; Rt, common transmural electrical
resistance.
aP < .01 (vs control).
bP < .05 (vs active CD).
March 2017 Epithelial Barrier in Celiac Disease 155CD patients (Table 1). Ultrastructurally, TJ strands were
shown to be altered severely, showing a reduced number of
strands as well as strand discontinuities. Again, a GFD was
shown to reverse the defects only partially, introducing the
potential of an intrinsic celiac barrier defect.70With regard to
the molecular TJ composition, integral TJ proteins are
differentiated from scaffolding proteins that are localized
intracellularly and are associated with the TJ, mostly via
PDZ-domains such as the zonula occludens (ZO) proteins.71
The former are categorized further in single trans-
membrane proteins as junctional adhesionmolecule proteins
or tetraspanning proteins as either the claudins or the
TJ-associatedMyelin and lymphocyte And Related protein for
VEsicle trafﬁcking and membrane Link (MARVEL) proteins.
In CD, the molecular counterpart to the TJ strand defects is a
complex alteration of integral TJ proteins and includes the
down-regulation of barrier-forming claudins including
claudin-3, claudin-5, and claudin-7, as well as the up-
regulation of channel-forming claudins such as claudin-2
and claudin-15.52,72 The role of occludin is still not certain,
with evidence pointing to a sealing function against macro-
molecular passage73 and wound healing.74 On the molecular
level, the interaction of occludin and the TJ-associated
molecule ZO-1 is defective, resulting in reduced levels of
phosphorylated ZO-1.75Epithelial Polarity as a Process to Regulate
Tight Junction Permeability
The complex TJ defect described in CD mucosae suggests
a coordinating master regulation. A genetic candidate
approach showed 2 regulators of epithelial polarity,
Partition-defective (Par-3) and Membrane-associated
guanylate kinase, WW and PDZ domain-containing protein
2 (Magi2), to play a role in the CD barrier defect.76 This
insight raises the immediate question of how mechanisms of
cell polarity might contribute to TJ integrity? Central to the
process of epithelial polarity is the well-conserved
partitioning defective protein (HUGO Gene Nomenclature:Par family cell polarity regulator) that was discovered in the
nematode Caenorhabditis elegans, where it regulates the
ﬁrst asymmetric cell division of the zygote.77,78 Intriguingly,
most of the polarity proteins show a polarized distribution
within the cell. Although Par-1, a serine/threonine kinase,
together with the proteins Lgl and Scribble, is restricted to
the basal cell compartment, Par-6, Cdc42, atypical protein
kinase C (aPKC), Crumbs, and Pals1 are localized to the
apical membrane and Par-3 is localized to the junctional
complex (Figure 3).79 Because membrane-associated Par
proteins have the capability to diffuse freely between
membrane domains, the system has to be regulated
tightly by a mechanism of active exclusion (mediated by
phosphorylation and by direct protein–protein interactions)
to induce and maintain the functionally important
polar distribution of polarity proteins.80 Par-3, as a PDZ-
domain–containing scaffolding protein, can associate with
aPKC-l and aPKC-z and Par-6 to form an apical polarity
complex that orchestrates the formation of the apical junc-
tional complex.81,82 Although Ser-827 phosphorylation of
Par-3 by aPKC induces association with the junctional
membrane, Ser-144 and Ser-885 phosphorylation by Par-1
and consecutive binding to the 14-3-3 protein Par-5 ascer-
tains exclusion of Par-3 from the lateral cell membrane.83
Interestingly, the Par-3 defect found in epithelia of CD pa-
tients closely resembles the phenotype of drosophila cells
that express a phosphorylation-defective mutant of the
protein homologous to human Par-3. These cells are
defective in performing lateral exclusion of Par-3.52,84 As a
presumptive consequence of this process in Drosophila ﬂies
as well as small intestinal mucosa from patients with CD,
Par-3 is allowed to spread out to the lateral membrane and
the cytosol rather than to focus at the apical junction,
resulting in the aforementioned complex celiac TJ defect
(Figure 4A). Moreover, protein phosphatase-1, mediating
dephosphorylation of Par-3, is down-regulated, also
contributing to reduced levels of Par-3 at the TJ.52,79,85 Both
processes add to an apparent deceleration of TJ formation
that matches the phenotype of a defective celiac TJ. Inter-
estingly, passage of the macromolecule biotin was found
only in areas of disorganized Par-3 and claudin-5 membrane
localization (Figure 4B). Another fascinating player in
epithelial polarity is the serine/threonine kinase Par-4,
better known under its tumor-suppressor name Lkb1.
Par-4 phosphorylation conveys activity to the previously
described Par-1 and thereby might play an initiator role in
polarity.86 Accordingly, activation of Par-4 was shown to be
sufﬁcient to induce polarity in intestinal epithelial cells,
even in the absence of apical junctions.87 Furthermore, Par-
4/Lkb1 interacts in a kinase-independent fashion with the
guanine exchange factor p114RhoGEF and, via activation of
RhoA, contributes to maturation of primordial junctions to
tight junctions.88 On the other hand, loss of Par-4/Lkb1 by
missense mutations results in Peutz–Jeghers syndrome, an
autosomal-dominant disorder that is characterized by
mucocutaneous pigmentation and gastrointestinal hamar-
tomatous polyps, but also various cancers including small
intestinal and colon cancer.89 Thus, future research on Par-4
might uncover principles on polarity mechanisms that
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March 2017 Epithelial Barrier in Celiac Disease 157contribute to a process such as epithelial-to-mesenchymal
transformation and thus be important to pathologies as
inﬂammation and tumorigenesis.
Impact of Zonulin on Tight Junction
Permeability in Celiac Disease
An intensely discussed mechanism of modulating TJ
permeability was brought forward by Alessio Fasano’s
group,90 who identiﬁed zonulin as an endogenous homo-
logue to the ZO toxin of Vibrio cholerae. Evidence was pre-
sented that ZO toxin as well as zonulin reversibly opens
small intestinal TJs by a signaling pathway that includes the
transactivation of the EGF receptor.91 Furthermore, recent
data have indicated that AT-1001, a peptide with the
terminal amino acid sequence of ZO toxin, affects the
gliadin-dependent F-actin rearrangement.92
Zonulin was shown to be secreted by IECs and LP
macrophages upon gliadin exposure and thus might be part
of a general inﬂammatory gut reaction.91,93,94 Consistent
with this, zonulin also has been associated with bacterial
gastrointestinal infections, rheumatoid arthritis, systemic
lupus erythematosus, and type 1 diabetes mellitus.95,96 Thus,
zonulin is neither speciﬁc for CD nor is zonulin unique
because other proinﬂammatory mediators of barrier and TJ
down-regulation have been found to be released in active CD,
namely tumor necrosis factor a and interferon-g.97,98
Therefore, deﬁnition of the role of zonulin in CD patho-
genesis remains controversial because almost 2 decades
after the ﬁrst publication on zonulin, (1) no zonulin
inhibition approach has been presented that completely
blocked the barrier defect in CD patients, (2) zonulin con-
centrations affecting barrier function are surprisingly high,
and (3) the exact identity of zonulin that has been proposed
to be identical to prehaptoglobin-2 still is controversially
discussed.91 Nevertheless, this concept recently has reached
the clinical bedside as larazotide, a drug targeting the
zonulin system, which was explored in CD patients as a
supplement to a gluten-free diet (see later).
Functional Impact of a Defective Paracellular
Barrier in Celiac Disease
The integrity of the epithelial barrier including normal TJ
function guarantees that transcellularly absorbed solutes do
not leak back into the lumen via the paracellular route.Figure 4. (See previous page). Distribution of TJ and polarity
1 and Par-3 ﬂuorescence signals in control and CD small intes
lateral membrane (small arrows). The diagrams in the right row p
as indicated by the long arrow in the laser scanning microscopy
were subjected to a combined calcium switch and biotin translo
monitored throughout the experiment. Filters were biotinylated
defects and then immunostained (Par-3, red; claudin-5, green;
[DAPI], blue). Orthogonal views are presented to illustrate dif
integrity of the TJ expressing Par-3 and claudin-5. Before ethy
(EGTA) treatment, biotin is excluded from the basal compartm
EGTA-treated cells (red arrows). After calcium replenishment th
biotin are found next to disorganized TJ strands permeable for b
panels, arrows). Reprinted with permission from Schumann et aHowever, in the case of a defective barrier, an uncontrolled
paracellular ﬂux of solutes and water into the intestinal
lumen may occur and contribute to what therefore has been
named a leak-ﬂux diarrhea. This has been functionally
implicated in a number of gastrointestinal disorders,
including Giardia lamblia infection, human immunodeﬁ-
ciency virus enteropathy, Clostridium difﬁcile colitis, and
also to Crohn’s disease and ulcerative colitis.99–105
In CD, leak-ﬂux diarrhea appears to be a major contrib-
uting mechanism in diarrhea pathophysiology because
additional secretory activity could not be identiﬁed.106 One
additionally should consider osmotic mechanisms, espe-
cially for the case of lactose, which is maldigested secondary
to a loss of small intestinal lactase.
However, it is still a matter of debate whether the
increased paracellular permeability contributes to the
uptake of gliadin peptides or if this occurs exclusively
transcellularly.
Uptake of Gliadin by the
Intestinal Mucosa
Secondary to the lack of prolyl and glutamyl endopep-
tidases in the human gastrointestinal tract, human beings
are incapable of completely digesting gliadins to a dipeptide
or tripeptide level. Thus, oligopeptides and polypeptides as
large as the a-gliadin 33mer remain in the intestinal lumen
and are detectable even in the colon.107 The question arises,
how peptides such as the a-gliadin 19mer that induce the
innate MIC-A response or the immunodominant 33mer are
taken up by IECs? Two decades ago, after having shown the
severely altered celiac TJ structure by freeze fracture
electron microscopy, a paracellular pathway seemed to be
obvious.70 However, many researchers challenged this
hypothesis, doubting that macromolecules as large as 2–4
kilodaltons would pass an epithelial barrier that merely is
altered with regard to its TJs. More recent research pro-
vided evidence for a transcellular pathway instead. Most
signiﬁcantly, Heyman’s laboratory uncovered a soluble
immunoglobulin A (sIgA)-dependent uptake pathway for
gliadin peptides.33,108,109 Although CD71, a transferrin re-
ceptor, usually is expressed basolaterally in IECs, it is
expressed at the apical IEC membrane in CD mucosae. An
elegant study using intramucosal ﬂuorescence resonance
energy transfer proved binding of gliadin peptides thatcomplex proteins in CD. (A) Confocal LSM recordings of ZO-
tinal mucosae. ZO-1 and Par-3 signals spread out along the
resent apical-to-basal signal proﬁles along lateral membranes
(LSM) ﬁgure. Scale means ±SEM, *P < .05. (B) Caco-2 cells
cation experiment with transepithelial resistance (TER) being
apically at the indicated time points to uncover local barrier
biotin/streptavidin, white; and 40,6-diamidino-2-phenylindole
ferences in apico–basal biotin passage associated with the
lene glycol-bis(b-aminoethyl ether)-N,N,N0,N0-tetraacetic acid
ent. Biotin deposits appear underneath dysfunctional TJs in
e TJ partially is reorganized (ie, belt-like TJs impermeable for
iotin as seen in the x-y-z collapsed stack projection; inserted
l.52
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CD71.109 Inhibition experiments using an array of immu-
noglobulin competitors showed functionality and speciﬁcity
of luminal-to-subepithelial gliadin transport.33 Studies in
IEC lines have suggested that trafﬁcking of apically inter-
nalized gliadin involves the apical endosome and baso-
lateral secretion.52,110,111 The mechanism underlying the
ectopic expression of CD71 at the apical membrane is
unclear. However, one should keep in mind that trafﬁcking
of CD71 is considered to be organized within polarity
processes.87
One as yet unresolved issue is whether a speciﬁc
trigger exists that can induce peaks of gliadin trans-
location and thereby potentially induce active disease
periods. In this regard it is worthwhile to hypothesize that
again polarity of epithelia might be a key determinant.
Because established triggers of depolarization include
infections (or merely colonization?) with speciﬁc micro-
biota and a switch in polarity is sufﬁcient to boost
transcytosis of macromolecules, this mechanism appears
to be an attractive hypothesis to explain outbreaks of CD
activity.112,113
Role of Barrier Dysfunction in Celiac
Disease for the Liver
It has been proposed that liver function is compromised
as a consequence of CD because the celiac intestinal barrier
defect is assumed to lead to the development of a reversible
hepatitis that frequently is found in active CD patients with
increased transaminase levels that normalize upon intro-
duction of a GFD.114 Of note, using an in vivo permeability
test, it already was shown early on that the occurrence of an
intestinal barrier defect and the development of a trans-
aminitis are correlated signiﬁcantly in CD patients.115 This
ﬁnding corresponds to current ideas on the existence of an
amplifying loop in liver diseases that is initiated after
proinﬂammatory cytokine secretion by hepatocytes and
consecutively leads to an intestinal barrier defect.116 This
defective barrier function is mechanistically complex and
allows for paracellular passage of bacterial products and
transcellular passage of whole bacteria via the portal vein to
the liver, where it aggravates the pre-existing liver dam-
age.117 However, another explanation for the transaminase
levels in CD could be that circulating serum proin-
ﬂammatory cytokines intensify hepatocyte apoptosis.
Treatment Options for Celiac Disease
That Target Barrier Defects
The only treatment for CD established to date is a strict
and life-long gluten-free diet. This induces mucosal healing
with regard to the small intestinal architectural defects
within weeks to months, presumably by abolishing
T-cell–mediated immune activation. In vivo and ex vivo data
have indicated that barrier function partially is restored
with normalizing lactulose/mannitol permeabilities after
implementation of a GFD, as well as partial remission of
resistance defects measured in the Ussing chamber–basedone-path impedance analysis on mucosal explants of CD
patients on GFD (Table 1).
However, new therapies for CD are anticipated by the
community, because adherence to a GFD results in a
reduced quality of life, and various studies have reported
alarmingly high percentages of CD patients being unable
for various reasons to adhere to the diet sufﬁciently.
Promising approaches include preparations of endopepti-
dase enzymes that effectively cleave gliadin peptides and
thereby circumvent gliadin-associated immune activation,
vaccination for relevant gliadin epitopes to induce oral
tolerance to gluten, and transglutaminase inhibitors that
will reduce afﬁnity of gliadin peptides for T cells and
thereby might ameliorate the T-cell response to gluten. It is
to date unknown if the intestinal barrier is targeted
directly or indirectly by these therapies. Nevertheless, with
larazotide acetate (formerly named AT-1001), a barrier-
targeting drug approaches the market. Previous in vitro
data have suggested that larazotide is capable of stabilizing
TJs and in vivo data included evidence for improving
barrier function.118,119 However, subsequent studies on
larazotide in CD patients failed regarding the primary goal
to stabilize the intestinal barrier as assessed by the
lactulose-to-mannitol ratio.120,121 Moreover, larazotide
treatment does not revert a ﬂat celiac mucosa into an
intestinal mucosa with normal architecture. On the other
hand, a low dose of larazotide reproducibly improved GI
symptoms. Thus, the last study published on larazotide in
CD suggested that patients suffering from persistent GI
symptoms despite adherence to a GFD might beneﬁt from
GFD plus larazotide.122Summary and Future Directions
Almost certainly the development of new treatment
concepts for CD-related barrier defects requires a funda-
mental understanding of the mechanisms triggering the
barrier defect including disclosure of the function of those
genes that are believed to convey a defective epithelial
barrier in CD. However, uncovering these mechanisms not
only might open the door to new, barrier-effective
therapeutics, but also identify as yet unknown additional
triggers that contribute to CD development in genetically
predisposed individuals.References
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